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AbstrACt
Objective Mental health problems are more prevalent 
in people with than without intellectual disabilities, yet 
treatment options have received little attention. The aim of 
this study was to identify and evaluate the effectiveness 
of pharmacological and psychological interventions in 
the treatment of mental health problems in children and 
adults with severe and profound intellectual disabilities, 
given their difficulties in accessing standard mental health 
interventions, particularly talking therapies, and difficulties 
reporting drug side effects.
Design A systematic review using electronic searches of 
PsycINFO, PsycTESTS, EMBASE, MEDLINE, CINAHL, ERIC, 
ASSIA, Science Citation Index, Social Science Citation 
Index and CENTRAL was conducted to identify eligible 
intervention studies. Study selection, data extraction and 
quality appraisal were performed by two independent 
reviewers.
Participants Study samples included at least 70% 
children and/or adults with severe or profound intellectual 
disabilities or reported the outcomes of this subpopulation 
separate from participants with other levels of intellectual 
disabilities.
Interventions Eligible intervention studies evaluated a 
psychological or pharmacological intervention using a 
control condition or pre-post design.
Outcomes Symptom severity, frequency or other 
quantitative dimension (e.g., impact), as assessed with 
standardised measures of mental health problems.
results We retrieved 41 232 records, reviewed 573 full-
text articles and identified five studies eligible for inclusion: 
three studies evaluating pharmacological interventions, 
and two studies evaluating psychological interventions. 
Study designs ranged from double-blind placebo controlled 
crossover trials to single-case experimental reversal 
designs. Quality appraisals of this very limited literature 
base revealed good experimental control, poor reporting 
standards and a lack of follow-up data.
Conclusions Mental ill health requires vigorous 
treatment, yet the current evidence base is too limited to 
identify with precision effective treatments specifically for 
children or adults with severe and profound intellectual 
disabilities. Clinicians therefore must work on the basis 
of general population evidence, while researchers work 
to generate more precise evidence for people with severe 
and profound intellectual disabilities.
PrOsPErO registration number CRD 42015024469.
IntrODuCtIOn 
Intellectual disabilities affect approximately 
1% of the population and are characterised by 
significantly impaired intellectual and adap-
tive skills with onset before adulthood. Their 
prevalence of mental health problems has 
been reported to be more than seven times 
higher than for the general population.1 
People with severe and profound intellectual 
disabilities, as indicated by an IQ of less than 
40, have limitations in problem-solving skills, 
cognitive and communication skills which 
can affect their ability to cope with stressful 
life events. The life circumstances of people 
with an intellectual disability may increase 
their risk of developing mental health prob-
lems or experiencing mental distress. Factors 
that have been identified as protective in 
adults without intellectual disabilities, such as 
employment opportunities, meaningful day 
activities and socially supportive networks, 
may be less likely to be present for people 
strengths and limitations of this study
 ► To our knowledge, this is the first systematic review 
focused on interventions to improve the mental 
health of both children and adults with severe and 
profound intellectual disabilities.
 ► Review eligibility was not restricted to randomised 
controlled trials which limits the strength of the re-
view’s findings.
 ► The body of evidence we identified was very slim and 
does not allow for generalisation of findings for ei-
ther psychological or pharmacological interventions.
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with intellectual disabilities and with additional impact 
for those with severe and profound intellectual disabil-
ities compared with those with mild or moderate intel-
lectual disabilities.2–4 Genetic factors may further increase 
the vulnerability of some people with intellectual disabil-
ities for mental health problems, as evidenced by signifi-
cant comorbidity rates of anxiety problems and psychosis 
in people with intellectual disabilities and certain genetic 
syndromes.5–9 
Mental health problems are as common in people 
with severe and profound intellectual disabilities as in 
people with mild or moderate intellectual disabilities, 
reported to have a point prevalence of 22.4%.10–14 Their 
treatment of mental health problems requires partic-
ular attention for three main reasons. First, longitudinal 
research investigating the mental health of children and 
young people with intellectual disabilities over a 14-year 
period suggests recovery may be poorer for those with 
severe intellectual disabilities, and therefore standard 
treatments may be suboptimal.10–12 Second, given their 
limitations in communication skills and understanding, 
people with severe and profound intellectual disabili-
ties cannot be assumed to find talking therapies such 
as cognitive–behavioural therapy (CBT)-based interven-
tions as accessible as other people do; yet these therapies 
are considered first-line treatments of choice for many 
types of mental health problems. Third, it is possible that 
people with intellectual disabilities are more sensitive to 
the side effects of pharmacotherapies, or have greater 
difficulties in reporting side effects when these occur, 
so raising the potential of more serious consequences, 
and the need for different dosing regimens compared 
with other people. The high prevalence and potentially 
persistent mental health problems experienced by people 
with severe and profound intellectual disabilities thus call 
for effective interventions to treat such problems and to 
promote well-being.
Existing systematic reviews have evaluated either the 
psychological or pharmacological treatment of mental 
health problems in people with intellectual disabilities. 
CBTs were found to have moderate positive treatment 
effects for people with intellectual disabilities who expe-
rience anger problems, anxiety and depression,15–17 but 
these findings are limited to adults with mild to moderate 
intellectual disabilities, however, as children or individ-
uals with severe and profound intellectual disabilities 
were not represented in the primary studies. Reviews of 
pharmacological interventions have largely focused on 
behaviour problems independent of their association 
with mental health problems. For example, potentially 
effective interventions for behaviour problems in adults 
with intellectual disabilities include risperidone, lithium 
and antiepileptic mood stabilisers.18 19 However, the meth-
odological quality of the evidence and registered adverse 
effects indicate that the use of these pharmacological 
agents requires caution.18 19 While behaviour problems 
can be associated with mental health problems and take 
on a precipitating or perpetuating role, they are more 
indicative of emotional dysregulation than of psychiatric 
symptomatology, and have been demonstrated in robust 
studies to be distinct from other types of mental health 
problems.20 We have not identified reviews on treatment 
response and side effects to pharmacotherapies for other 
types of mental health problems experienced by people 
with severe and profound intellectual disabilities. The 
objective of the present systematic review was to eval-
uate the effectiveness of psychological and pharmaco-
logical treatments for mental health problems and their 
key symptoms in both children and adults with severe or 
profound intellectual disabilities.
MEthODs
The review was conducted and written in accordance with 
the Preferred Reporting Items for Systematic Reviews 
and Meta-Analyses (PRISMA) statement.21 The review 
protocol was registered with PROSPERO, Centre for 
Reviews and Dissemination, under the reference number 
CRD 42015024469.
search strategy
The search strategy was developed for two conjoint system-
atic reviews focused on the evaluation of both measures 
of and interventions for mental health problems in 
people with severe and profound intellectual disabili-
ties. Although separate search terms were used for each 
systematic review, records identified through the respec-
tive searches were pooled together prior to the study 
eligibility screening to ensure that studies piloting an 
assessment as an intervention outcome measure would 
also be identified.
Initial systematic searches were conducted in the week 
of 13–17 July 2015 for the following databases: PsycINFO, 
PsycTESTS, EMBASE, MEDLINE, CINAHL, ERIC, ASSIA, 
Science Citation Index, Social Science Citation Index, 
and Cochrane Central Register of Controlled Trials 
(CENTRAL). Searches used Boolean terms to combine 
search strings for intellectual disabilities, mental health 
and psychological or pharmacological interventions. 
Instead of listing all potential diagnosis and treatments 
the search strategy included the most common diagnoses 
and treatments in conjunction with more general mental 
health descriptions. This approach could limit the initial 
records to be screened, whereas relevant studies could still 
be identified through the ancestry method which screens 
citing and cited articles of included studies and through 
contact with authors. A sample search strategy for the 
PsycINFO, PsycTESTS and ASSIA searches is provided in 
the online supplementary appendix. Full search strate-
gies for each database can be requested from the authors.
Searches were updated in September 2017, to cover 
the time period from the original searches, and no new 
studies were identified from these searches. The updated 
searches followed the same search strategy and study 
screening protocol as the original searches.
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study eligibility criteria
The following inclusion criteria were applied to (1) publi-
cation type, (2) study design, (3) participants, (4) inter-
ventions and (5) outcomes.
Publication
Peer-reviewed publications written in English, French, 
German or Dutch were eligible for review.
Study design
The following study designs were eligible for inclusion 
in the review: (A) randomised controlled trials, (B) 
controlled trials without randomisation, (C) single-group 
pre-post designs, (D) case series with outcome measures 
reported as group mean data, (E) single-case experi-
mental designs and (F) case–control studies. Observa-
tional and retrospective cohort studies, as well as case 
studies without a control condition or a return to base-
line, were excluded.
Participants
To ensure that the outcome data were representative for 
people with severe and profound intellectual disabilities 
it was required that either a minimum of 70% of partic-
ipants were diagnosed or reported as having severe or 
profound intellectual disabilities, or that data for partic-
ipants with severe or profound intellectual disabilities 
were reported separately in the study. Although this was 
an arbitrary criterion, this was to ensure that a majority 
of people with severe or profound intellectual disabilities 
were in the study samples. Studies that did not provide 
any usable information about the level of intellectual 
disabilities within samples were excluded. No exclusions 
were applied concerning participants’ age or gender or 
any other characteristics except for degree of intellectual 
disability.
Intervention
Eligible psychological interventions were delivered by a 
trained lay therapist or qualified professional who system-
atically applied interventions based on well-established 
psychological principles and techniques directly to the 
person with an intellectual disability, either individually 
or in a group. For pharmacological interventions, it was 
expected that the pharmaceutical agent was given with 
regular review by a qualified medical practitioner or 
health professional, and recognised at least in principle 
as a potential treatment for a mental health problem/
symptom.
Outcomes
Eligible outcomes were standardised assessments of 
mental disorders or their key symptoms which have a 
significant impact on daily functioning. However, we 
acknowledge that defining the mental and physical 
components of mental and physical disorders into mutu-
ally exclusive categories can be challenging, not in the 
least because certain components are symptomatic of 
multiple disorders and certain disorders have shown 
high rates of comorbidity with one another. For the 
purpose of this systematic review, the inclusion criteria 
for mental disorders and their symptoms were derived 
from the Diagnostic and Statistical Manual of Mental 
Disorders Fourth Edition (DSM-IV),22 as this version was 
most likely to be used by the primary studies to be iden-
tified by the systematic review. Mental and behavioural 
disorders, and their key symptoms, eligible for review fell 
within the following classifications: (A) attention-deficit 
and disruptive behaviour disorders, (B) tic disorders, (C) 
other disorders of infancy, childhood or adolescence, (D) 
schizophrenia and other psychotic disorders, (E) mood 
disorders, (F) anxiety disorders, (G) somatoform disor-
ders, (H) factitious disorders, (I) dissociative disorders, 
(J) eating disorders, (K) adjustment disorders and (L) 
personality disorders.
Studies focused on key symptoms of mental disor-
ders were included as not all treatment offers a holistic 
approach, and interventions may instead aim to alle-
viate one or more symptoms of a disorder. By contrast, 
challenging behaviours and behaviour problems may be 
associated with or indicative of underlying mental disor-
ders20 23 but are not recognised as a key diagnostic feature 
of the above listed mental disorders and are hence 
excluded from this review.
The broad scope of the systematic review in terms of 
study designs, type of interventions and range of partic-
ipants was advised as initial scoping searches indicated 
that only few studies included individuals with severe and 
profound intellectual disabilities.
A single post hoc exclusion criterion was applied to 
exclude records from the searches published prior to 
1980 (n=106 records, but not fully checked for inclusion 
criteria), coinciding with the publication of the DSM-III.24 
This assured a minimal level of consistency in the recog-
nition and diagnosis of mental health problems from 
DSM-III through to DSM-IV. It is likely that there would 
have been a delay between the publication of the DSM-III 
and its first use in published research, but searches back 
to 1980 were essential to ensure that no potentially rele-
vant studies were missed.
study selection
Data collection and abstract screening were performed 
by the first author (LV). Twenty per cent of records were 
also screened by the second author (SF), leading to an 
overall agreement rate of 99.8% and a kappa coeffi-
cient of 0.91 for studies to proceed to full-text evalu-
ation. Second screening a proportion of results is an 
accepted practice when a review is large and resources are 
limited.25 The overall inclusion rate for the screening of 
titles and abstracts was 2.3%. Full-text review of 573 arti-
cles was performed independently by the two reviewers 
(LV and SF), which resulted in a kappa coefficient of 
0.76 for inclusion in the review and the data extraction 
stage. Eleven disagreements between the two reviewers 
were resolved through joint discussion. All disagree-
ments concerned the proportion of participants with 
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severe and profound intellectual disabilities and were not 
related to study design, intervention or outcomes. The 
review of one full-text article required consultation with 
the third author (RPH) to determine whether this study 
met the review eligibility criteria regarding mental health 
outcomes. Upon discussion, the paper was excluded from 
the review.
Next, reference lists and citation records of all included 
studies were screened to identify additional papers that 
may not have fulfilled the search term criteria. No addi-
tional studies were identified in this way.
Data extraction and quality synthesis
Data extraction was conducted by the second author 
and reviewed by the first author for variables including: 
study design, study population, intervention, outcome 
measures and follow-up data.
The certainty in the evidence for each outcome 
measure could not be assessed with the Grades of Recom-
mendation, Assessment, Development and Evaluation 
approach,26–28 as used by the Cochrane collaboration and 
national guideline organisations such as National Insti-
tute for Health and Care Excellence (NICE) in the UK, 
due to the incomparability of identified studies in terms of 
study design, interventions and outcomes. Likewise, it was 
not possible to conduct a meta-analysis or provide other 
summary measures because no two studies addressed the 
same mental health problem using a similar intervention.
Both reviewers independently performed a critical 
appraisal of all included studies. No disagreements were 
recorded at either stage. The assessment followed the 
Critical Appraisal Skills Programme (CASP)29 30 Check-
lists or the quality indicators for within single-subjects 
research,31 dependent on the study design.
Patient and public involvement
Patients and public were not involved in the conception, 
development or implementation of this systematic review, 
nor in the selection of outcome measures and the inter-
pretation of the study findings.
rEsults
The search strategy for the conjoint systematic review 
identified 24 883 unique records, of which 573 were 
retained for full-text eligibility screening. The study 
selection process is illustrated in figure 1. Excluded arti-
cles most commonly did not meet the eligibility criteria 
concerning the severity of intellectual disabilities of study 
participants (n=242). Initial records were also excluded 
based on their study design (n=113), a publication date 
prior to 1980 (n=106), because the intervention or 
outcomes were not focused on recognised mental health 
Figure 1 Preferred Reporting Items for Systematic Reviews and Meta-Analyses (PRISMA) flow diagram. ID, intellectual 
disability.
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problems (n=59), due to their publication status (e.g., 
conference abstracts; n=38), or because the full-text paper 
could either not be retrieved (n=6) or was published in 
a non-eligible language (n=4). In total, five studies were 
included in the review and are described in table 1. Three 
studies included only adults with intellectual disabilities: 
a double-blind placebo controlled crossover trial32 and 
a single-case experimental reversal design of pharmaco-
therapy,33 as well as a single-case experimental reversal 
design of a psychological intervention.34 Two studies 
included children and young people: a randomised trial 
of pharmacotherapy by White and Aman35 and a single-
case study of a psychological intervention for a 13-year-old 
girl.36
Psychological interventions
Two studies evaluated interventions based on psycholog-
ical principles. Interventions were offered for symptoms 
of depressive disorder, and to manage tic frequency in 
Gilles de la Tourette syndrome.
In a single-case experimental ABAB design, Lindauer 
and colleagues34 offered an enriched environment 
for the management of major depressive disorder in a 
23-year-old woman with severe intellectual disabilities 
who also presented with self-injurious behaviour. Pre-ex-
isting treatment of the mood disorder with carbamaze-
pine (5.3 mg/kg/day) was continued during the study. 
The enriched environment setting was a 3 m×3 m padded 
room, in an inpatient unit, in which stimuli were present 
that were chosen following a paired-choice assessment to 
identify the woman's preferred stimuli and assess signs 
of positive and negative affects. Smiling, giggling and 
laughing were considered examples of positive ‘affect’, 
whereas frowning, whining, crying and verbal expres-
sions such as ‘I am sad’ were identified as signs of nega-
tive ‘affect’. No other outcome measures relating to the 
mood disorder were employed. Behavioural observations, 
through a one-way mirror, showed that the enriched envi-
ronment increased signs of positive affect and decreased 
signs of negative affect, in particular during the second 
intervention phase. The lack of follow-up measures and 
the delivery of interventions in a padded room in an inpa-
tient setting reduce the ecological validity of this inter-
vention. Likewise, the replicability of findings is impeded 
in terms of participant selection and intervention fidelity 
(see table 2).
Zarkowska36 adopted a basic single-case experimental 
design to examine interventions for vocal and motor tics 
in a 13-year-old girl with Gilles de la Tourette syndrome 
and severe intellectual disabilities. Two treatment probes, 
cued relaxation and interruption, were evaluated using 
an ABA return to baseline design for each intervention 
comprised of a 5 min baseline recording, a 5 min interven-
tion and a 5 min postbaseline recording. Cued relaxation 
appeared to lead to better outcomes but neither interven-
tion had lasting effects and interruption increased vocal 
tic frequency. The study design showed strong external 
and social validity and provided clear descriptions of 
dependent and independent variables (see table 2). 
However, internal validity was weak and the ABA design 
was not the most suitable for demonstrating experimental 
control. Following the evaluation of treatment probes, 
the study continued as an A-B case study implementing 
successive interventions of relaxation training, treatment 
with clonidine and treatment with pimozide. Due to 
the non-controlled nature of these interventions, their 
respective outcome data and follow-up data were not 
considered eligible for inclusion in this review.
The replicability of findings from both studies is 
hindered by a lack of information regarding partic-
ipant selection, physical setting of the intervention, 
implementation fidelity and the reliability of outcome 
measurements.
Pharmacological interventions
Two double-blind placebo controlled crossover trials 
and one single-case experimental reversal design eval-
uated pharmacological interventions for use in people 
with severe intellectual disabilities and mental health 
problems.
Aman and colleagues32 employed within-group rando-
misation of order of administration of 4-week treatment 
with imipramine, in a dosage of 3 mg/kg/day, and 4 
weeks with placebo, with 1-week drug-free in between. 
Interventions were offered to five adults with severe intel-
lectual disabilities and depressive symptoms, in addition 
to a group of five adults with acting-out behaviours. The 
latter were not eligible for inclusion in this review as these 
behaviours were not considered a mental health problem. 
Eligible depressive symptoms were based on evidence 
from prior research studies and required behavioural 
observation instead of information obtained from diag-
nostic interviews. Symptoms included ‘seclusion and 
social withdrawal, sleep loss, weight loss, tearfulness or 
the appearance of sad affect, and a pervasive lack of overt 
behavior’ (p 26531). Intervention effects were assessed 
with the Aberrant Behavior Checklist (ABC)37 and indi-
cated imipramine to have a detrimental effect on symp-
toms related to irritability, lethargy and hyperactivity, and 
no effect on stereotypical behaviours and inappropriate 
speech. Adverse effects were recorded but not described 
separately for the five adults with severe intellectual 
disabilities and depressive symptoms. For one person with 
affective symptoms, imipramine was found to improve 
behaviour and relieve chronic constipation.
White and Aman35 evaluated the use of pimozide on 
maladaptive behaviours and hyperactivity, in young people 
and adults with moderate to profound intellectual disabil-
ities. Following a 4-week baseline, the eight participants 
received two 4-week treatments with either pimozide, in 
a dosage of 0.12 mg/kg/day, or placebo, with a 1-week 
washout period between intervention phases. Treatment 
effects were evaluated using assessments with the ABC 
for the last 3 weeks of each intervention. Hyperactivity 
scores on the ABC reduced following the intervention, as 
did irritability levels, based on nurses’ behaviour ratings 
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of participants. No intervention effects were observed 
for ABC lethargy, stereotypy and inappropriate speech 
domains. Furthermore, behavioural observations also did 
not identify any treatment effects.
The methodological quality of these two studies was 
confirmed using the CASP quality appraisal checklist 
(see table 3). However, follow-up measures were notably 
absent and sample sizes too small to provide sufficient 
power for the conducted statistical analyses. Addition-
ally, the period of treatment was of too short duration, 
as imipramine can take up to 6 weeks to be effective in 
the general population, so that intervention was of poor 
design.
The only fully experimental single subject experi-
mental design study evaluated the effect of haloperidol 
on tic frequency in a 35-year-old woman with Gilles de 
la Tourette syndrome and severe intellectual disabili-
ties.33 Using an ABABA design, the dose of haloperidol 
was gradually increased during the intervention phases 
and maximal effectiveness was reached with the highest 
dosage of 10 mg/day. Weekly behavioural observation at 
the community residential setting where the participant 
Table 2 Quality appraisal of single-subject studies using the Quality Indicators within Single-Subject Research31
Quality indicator Lindauer et al34 Rosenquist et al33 Zarkowska36
Participant description and setting
Ability to select individuals with similar 
characteristics
Yes Yes Yes
Replicability of participant selection 
process
No No No
Replicability of physical setting Yes Yes Partial
Dependent variable
Described with operational precision Yes Yes Yes
Measured to generate a quantifiable index Yes Yes Yes
Measure is valid and replicable Yes Yes Yes
Measurements repeated over time Yes Yes No
Measures assessed in terms of reliability or 
interobserver agreement
Yes Yes No
Independent variable
Described with replicable precision Yes Yes Yes
Systematically manipulated and under 
control of experimenter
Yes Yes Yes
Overt measure of implementation fidelity No Not applicable No
Baseline
Repeated measurements baseline Yes Yes No
Described with replicable precision Yes Yes Yes
Experimental control/internal validity
Minimum of three demonstrations of 
experimental effect at three points in time
Yes Yes No
Controlling for threats to internal validity Unclear Yes Unclear
Document a pattern of experimental control Yes Yes Yes
External validity
Effects replicated across participants, 
settings or materials
Yes Yes No
Social validity
Dependent variable is socially important Yes Yes Yes
Magnitude of change is socially important Yes Yes Yes
Implementation of independent variable is 
practical and cost-effective
Yes Yes Yes
Implementation of independent variable 
over extended period of time, by typical 
intervention agents and in typical contexts
Yes Yes Yes
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lived showed reduced tic frequencies during mealtimes, 
nearing zero levels, and during waiting times. Interven-
tion effects reversed when the dose was lowered. These 
findings are considered reliable due to masked assess-
ment and reversal design, alongside the replicability of 
measures and intervention, see table 2.
Overall quality appraisal of the evidence base
Methodological quality of the identified studies was poor, 
with concern in terms of small sample sizes, lack of masked 
assessment and lack of follow-up measures. By contrast, 
reporting standards were generally high in terms of vari-
able descriptions and the internal and external validity of 
the results. Implications of the quality appraisal are inte-
grated in the study descriptions above, whereas a detailed 
overview of the quality review for each study is reported 
in tables 2 and 3.
DIsCussIOn
Despite their very high rates of mental health problems, 
there is a lack of research in interventions that explicitly 
target mental health problems in people with severe and 
profound intellectual disabilities. The scope of this review 
was wide. However, only five studies were eligible for 
inclusion and the findings are inconclusive at best. This 
is highly problematic for clinicians who have to manage 
these disorders and can only rely on the use of interven-
tions designed for the general population, despite the 
likely limitations and inaccessibility of these for people 
with severe intellectual disabilities.
Haloperidol was demonstrated to improve tics, but in 
a single person. Pimozide was reported to reduce hyper-
activity and other behaviour problems,35 but it is not a 
recognised treatment for hyperactivity in the general 
population; and NICE concludes that there is no evidence 
that antipsychotic drugs are of use in this condition 38. 
The sedative properties of pimozide can calm disturbed 
patients in the short term, but it is not recommended 
for long-term use in view of potential side effects, which 
includes death, and its use is therefore reserved for schizo-
phrenia only. While meeting the inclusion criteria of the 
review, the study is therefore outdated given subsequent 
advances in knowledge about this class of drugs. Imipra-
mine caused deterioration of affective symptoms, but the 
study was poorly designed by today’s standards, including 
the drug not being prescribed for long enough duration 
Table 3 Critical Appraisal Skills Programme (CASP Checklists)40 for studies with n>1
Quality indicator Aman et al32* White and Aman35*
Validity of the results
Study addresses a clearly focused issue Yes Yes
Cohort recruited in an acceptable way Yes Yes
Exposure accurately measured to 
minimise bias
Yes Yes
Outcome accurately measured to 
minimise bias
Yes Yes
Identification of all important 
confounding factors
Yes Yes
Design and/or analysis account for 
confounding factors
No: length of intervention too short to observe 
treatment effects
No: length of intervention too short 
to observe treatment effects
Complete enough follow-up of 
participants
No No
Long enough follow-up of participants No No
Scope of the results
Description of study results Yes Yes
Precision of study results No exact p values, no effect sizes, no 
differentiation between depressive-like and 
acting-out group
No exact p values, no effect sizes
Believability of study results Yes Yes
Impact of the results
Results applicable to local population Yes Yes
Results in line with available evidence No Yes
Implications for practice Length of intervention too short to draw 
conclusions regarding implications
The study is now outdated given 
improved knowledge on the risks of 
the long-term use of the drug
*CASP Checklists for randomised controlled trials.
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to be effective.32 Additionally, the use of imipramine has 
declined in the whole population since the introduction 
of selective serotonin reuptake inhibitors in the 1980s 
and other newer antidepressant agents, on the basis of 
side effect profile. Empirical evidence for current phar-
macological interventions has not yet been published.
Evidence for the effectiveness of psychological inter-
ventions is also weak in the absence of controlled trials 
or high-quality single-case experimental designs (such as 
multiple baseline approaches). Across intervention types, 
two studies aimed to reduce tic frequency in people with 
severe intellectual disabilities and Gilles de la Tourette 
syndrome yielding putative positive effects for relaxation 
techniques and treatment with haloperidol. Evidence 
relating to common mental health problems (eg, anxiety, 
depression) was notably very limited. Studies including 
children with severe and profound intellectual disabil-
ities involved different interventions than for studies 
with adults and while the geographic spread of the 
research was diverse, all included studies were conducted 
in English-speaking countries. Overall, a quantitative 
synthesis of the evidence was not possible due to the 
heterogeneity of the identified studies as no two studies 
addressed the same mental health problem with a similar 
intervention or similar outcome measures. Furthermore, 
the total sample size across the five identified studies was 
only 16 participants: nine children and seven adults, nine 
male and seven female. Finally, the review demonstrates 
that research in this area has stalled over the last decade. 
The most recent study we identified was published nearly 
two decades ago,34 while the methodologically stronger 
studies using controlled design employed outdated phar-
macotherapies that are currently not recommended due 
to their potential side effects.36 39
strengths and limitations
Strengths of this systematic review are the rigour with 
which it was conducted. In line with PRISMA guidelines, 
the prior publication of the review protocol enhances its 
transparency and replicability, while double reviewing of 
full-length articles and quality appraisal strengthens the 
findings. The current review improves upon previous 
reviews in this area by employing a broader scope to 
identify both psychological and pharmacological inter-
ventions for a range of mental health problems. In spite 
of this, our findings show that this area of research has 
received very little attention over the years with no recent 
treatment studies being identified and pharmacolog-
ical interventions having employed drugs that would no 
longer comply with today’s medical standards.
Limitations of the study relate to the search strategy. 
The systematic search did not include terms for every 
specific possible disorder or potential treatment, neither 
did it include a wide range of behavioural descriptions. 
In spite of this, we identified a considerably large number 
of potential records. Meanwhile, requiring at least 70% 
people with severe and profound intellectual disabili-
ties to be included in a sample where outcomes are not 
reported separately for this group was a pragmatic deci-
sion so people with severe and profound intellectual 
disabilities would be sufficiently represented in the review 
findings. However, reducing the required proportion of 
participants with severe and profound intellectual disabil-
ities to 50% would not have added any eligible studies (a 
post-hoc review check completed by the first author).
Explanations and implications
A major challenge in mental health research for people with 
severe and profound intellectual disabilities, including this 
systematic review, lies with the selection of study outcomes. 
The appropriateness of measures such as the ABC37 can 
be questioned when used to assess the wide spectrum of 
symptoms of mental health problems. However, the ABC 
was found to be one of the few reliable measures relating 
to mental health problems for individuals with severe and 
profound intellectual disabilities.40 Indeed, behavioural 
outcomes can assess key symptoms of mental disorders 
according to International Classification of Diseases 
10th Revision criteria, but can equally be associated with 
distress and reduced quality of life. While this diagnostic 
taxonomy was practical for conducting the systematic review, 
it may not be sufficient to evaluate all relevant interventions 
aimed at improving the general well-being of people with 
severe and profound intellectual disabilities.
The scarcity of trials addressing the mental health needs 
of people with severe and profound intellectual disabil-
ities is worrisome in light of the fact that they do experi-
ence mental health problems. Yet, there is awareness of the 
mental health needs in this population among researchers 
and clinicians as is evident from the wide range of descrip-
tive case reports, which did not provide empirical evidence 
for the effectiveness of an intervention. On a positive note, 
the 101 studies identified as including at least some individ-
uals with severe and profound intellectual disabilities show 
that this population is not routinely excluded from clinical 
practice evaluations. Although beyond the objectives of this 
systematic review, a scoping overview of the range of inter-
ventions evaluated in these studies and those being offered 
in routine clinical practice could help set the direction to 
guide future research. Establishing evidence-based inter-
ventions to treat mental health problems in people with 
severe and profound intellectual disabilities requires more 
research with stronger methodological designs.
Future directions
Challenging the status quo and developing an evidence 
base from which to treat people with severe and profound 
intellectual disabilities and mental health problems is a 
joint responsibility of practitioners and researchers. Bidi-
rectional knowledge transfer is particularly important 
in this regard: research into severe and profound intel-
lectual disabilities making its way into the training of 
practitioners, as well as practitioners highlighting diffi-
culties in assessment and treatment that need addressing. 
Commissioning and exploring funding opportunities to 
conduct research into evidence-based pharmacological 
copyright.
 o
n
 N
ovem
ber 18, 2019 at University of G
lasgow. Protected by
http://bmjopen.bmj.com/
BM
J O
pen: first published as 10.1136/bmjopen-2018-021911 on 19 June 2018. Downloaded from 
11Vereenooghe L, et al. BMJ Open 2018;8:e021911. doi:10.1136/bmjopen-2018-021911
Open access
and psychological interventions, and an open discussion 
regarding the ethical considerations of research involving 
people who may lack the capacity to consent also require 
attention. A large inequality in evidence for effective 
treatments for mental health problems is experienced by 
children and adults with severe and profound intellectual 
disabilities. Until this inequality is adequately addressed, 
health services need to provide treatments found to be 
effective for people with mild to moderate intellectual 
disabilities where they exist—although the availability of 
interventions for this population is also poor in compar-
ison to interventions for people without intellectual 
disabilities. Particular attention should be given to how 
these treatments might affect people with severe and 
profound intellectual disabilities differently regarding 
symptom presentation and outcome assessment. The 
accessibility of a range of psychological therapies should 
also be taken into account, as well asside effect reporting 
which may indicate a need for differences in dosing regi-
mens. Keeping detailed accounts of how treatments were 
subsequently modified will benefit the development of a 
more solid evidence base.
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